← Ablatotech Vitals
Hepatology EvidenceDigest

Long-term Outcomes of Hepatitis B Functional Cure Strategies

Hepatology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 1, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Achieving a functional cure in chronic hepatitis B (CHB)—defined as sustained hepatitis B surface antigen (HBsAg) loss with or without seroconversion—remains a key therapeutic goal to reduce long-term liver-related morbidity and mortality. Recent advances in antiviral therapy and immunomodulation have improved rates of functional cure, but it remains uncommon with current nucleos(t)ide analogues (NAs). Emerging data highlight the importance of host immune responses and novel treatment strategies to enhance durable viral control. Long-term follow-up studies confirm that functional cure is associated with improved clinical outcomes, but challenges remain in identifying predictors and optimizing treatment regimens (Zheng J et al., 2025; De Broucker et al., 2025).

Clinical bottom line

Achieving a functional cure in chronic hepatitis B (CHB)—defined as sustained hepatitis B surface antigen (HBsAg) loss with or without seroconversion—remains a key therapeutic goal to reduce long-term liver-related morbidity and mortality. Recent advances in antiviral therapy and immunomodulation have improved rates of functional cure, but it remains uncommon with current nucleos(t)ide analogues (NAs). Emerging data highlight the importance of host immune responses and novel treatment strategies to enhance durable viral control. Long-term follow-up studies confirm that functional cure is associated with improved clinical outcomes, but challenges remain in identifying predictors and optimizing treatment regimens (Zheng J et al., 2025; De Broucker et al., 2025).

What the evidence shows

Zheng J et al. (2025) review factors influencing functional cure in CHB, emphasizing that effective restoration of both innate and adaptive immunity is critical. They discuss mechanisms by which current therapies suppress viral replication but often fail to eliminate covalently closed circular DNA (cccDNA), the viral reservoir.

De Broucker et al. (2025) provide long-term follow-up data in children with CHB, demonstrating that spontaneous or treatment-induced functional cure leads to sustained HBsAg loss and reduced progression to cirrhosis or hepatocellular carcinoma (HCC). Their findings underscore the durability and clinical benefit of functional cure.

Zheng P et al. (2023) detail immune pathways involved in CHB pathogenesis and highlight potential therapeutic targets to enhance immune-mediated viral clearance.

Lee Soon Kyu et al. (2025) discuss the long-term safety and efficacy of tenofovir alafenamide (TAF), noting its favorable tolerability profile but limited impact on increasing functional cure rates, thus reinforcing the need for novel agents.

Vatan Aslı et al. (2026) explore biomarkers such as the pan-immune-inflammation value to predict functional cure in patients on long-term NA therapy, suggesting potential tools for personalized treatment.

Chang J et al. (2014), although older, remain authoritative in outlining therapeutic strategies aiming for functional cure, including combination therapies and immune modulators.

Caveats and uncertainty

Functional cure rates remain low with current standard-of-care NAs, often below 10%, necessitating prolonged therapy.

Heterogeneity in patient populations, viral genotypes, and immune status complicates prediction of functional cure.

Long-term safety and efficacy data for emerging immunomodulatory agents are limited.

Optimal timing and combination of antiviral and immune-based therapies require further investigation.

Biomarkers predicting functional cure are promising but not yet validated for routine clinical use.

How this may change practice

Clinicians should continue to prioritize viral suppression with NAs while recognizing the limitations regarding functional cure.

Emerging biomarkers may aid in identifying patients most likely to achieve functional cure and guide treatment duration.

Integration of novel immunotherapies and combination regimens may become standard as evidence matures.

Long-term monitoring post-HBsAg loss remains essential to detect relapse or HCC risk.

Patient counseling should emphasize the evolving nature of functional cure strategies and the importance of adherence.

Multidisciplinary care involving hepatology, virology, and immunology expertise will be critical for personalized management.


References

  1. Zheng J, et al. Achieving chronic hepatitis B functional cure: Factors and potential mechanisms. Virus Res. 2025; DOI:10.1016/j.virusres.2024.199507
  2. De Broucker C, et al. Functional Cure in a Long-term Follow-up of Children With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2025; DOI:10.1016/j.cgh.2024.09.008
  3. Zheng P, et al. Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity. Front Cell Infect Microbiol. 2023; DOI:10.3389/fcimb.2023.1206720
  4. Lee SK, et al. Long-Term Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B: Raising the Need for Studies on Functional Cure—Editorial on “Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B”. Korean J Gastroenterol. 2025; DOI:10.4166/kjg.2025.062
  5. Vatan A, et al. Pan-Immune-Inflammation Value and Functional Cure in Patients with Chronic Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy. Viral Hepat J. 2026; DOI:10.4274/vhd.galenos.2026.2026-8-3
  6. Chang J, et al. Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. Acta Pharm Sin B. 2014; DOI:10.1016/j.apsb.2014.05.002

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team